Metabolism: Hepatic, via CYP2C19 (major pathway) and CYP2C9 and CYP3A4; saturable
Bioavailability: 96%
Half-life elimination: Variable, dose-dependent. Steady-state is achieved by day 3 when an IV loading dose is administered and between days 5 and 8 if no loading dose is used